NVP-BAW2881 is a potent, selective VEGFR inhibitor with IC50 of 37 nM for hVEGFR2 (KDR).
NVP-BAW2881 also demonstrates activity against Tie2 (IC50=650 nM) and RET (IC50=410 nM), no activity against a wide panel of other kinases.
NVP-BAW2881 inhibits VEGF-A-induced phosphorylation of VEGFR-2 in HUVECs and in VEGFR-2-transfected CHO cells with IC50 of 2.9 and 4.2 nM, respectively.
NVP-BAW2881 also inhibits phosphorylation of RET, PDGFRβ and c-Kit with IC50 of 40-80 nM.
NVP-BAW2881 inhibits the proliferation, migration and tube formation by HUVECs and lymphatic endothelial cells in vitro.
NVP-BAW2881 displays strong anti-inflammatory effects in models of acute inflammation such as psoriasis.
